Market Overview

UPDATE: Goldman Sachs Downgrades Domtar to Neutral on Valuation

Share:
Related UFS
Benzinga's Volume Movers
The Price Of Paper Is Increasing As Companies Try To Stay Profitable In Electronic Age
Domtar acquires Butterfly Health (Seeking Alpha)

Goldman Sachs downgraded Domtar Corporation (NYSE: UFS) from Buy to Neutral and maintained an $89.00 price target.

Goldman Sachs said, "We downgrade Domtar shares to Neutral from Buy given we no longer expect producers will be able to implement a mid-year uncoated freesheet (UCFS) price hike, and as result we have reduced our 2013 EPS estimate for Domtar by 21%, and valuation now appears reasonable. In 2012, UCFS prices slipped, despite operating rates of 91%. As we forecast operating rates will be unchanged in 2013, we no longer forecast a mid-year hike. Since mid-May 2012, Domtar is +8% vs. S&P 500 +12%."

Domtar closed at $83.26 on Monday.

Latest Ratings for UFS

DateFirmActionFromTo
Apr 2016National BankDowngradesOutperformSector Perform
Apr 2016Bank of AmericaDowngradesNeutralUnderperform
Mar 2016CIBCInitiates Coverage onUnderperformer

View More Analyst Ratings for UFS
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (UFS)

View Comments and Join the Discussion!